

# Adoptive T-cell therapy

Cassian Yee

*Fred Hutchinson Cancer Research Center, Seattle, WA, USA*

## Abstract

Strategies that enhance the efficacy of adoptive therapy involve intrinsic factors such as the selection of desired effector cells and extrinsic factors such as patient conditioning. *Ex vivo* expanded antigen-specific T cell clones allows us to evaluate these factors in clinical trials for the treatment of patients with metastatic melanoma. In one trial, adoptively transferred antigen-specific CD8+ T cell clones were examined in patients following Fludarabine lymphodepletion; in the second, CD4 T cell clones were administered in a dose escalation study. The safety, duration of *in vivo* persistence, and anti-tumor efficacy of these trials will be presented along with considerations for future studies.